TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.
Investors & News
9/2023 | TAE Life Sciences
TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for in-hospital BNCT at ASTRO 2023 Annual Meeting
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, is thrilled to announce it is bringing BNCT to this year's annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.
9/2023 | TAE Life Sciences
TAE Life Sciences to Present Its Latest advancements in Radiation Oncology at LSI Europe 2023
TAE Life Sciences (TLS), a pioneer in accelerator-based Boron Neutron Capture Therapy, announces its participation in the upcoming LSI Europe 2023 conference. The event, set to take place in Barcelona from September 18-22, will serve as a platform for TAE Life Sciences' CEO, Rob Hill, to deliver a keynote presentation on the future of radiation oncology, and the company's revolutionary BNCT system and proprietary BNCT drugs.
8/2023 | PR Newswire
TAE Life Sciences Signs Biddle Sawyer to Manufacture Boronated TC220 Drug for BNCT Cancer Treatment
TAE Life Sciences has today announced a landmark agreement with Biddle Sawyer to serve as the exclusive supplier of TC220, a novel boronated amino acid analog drug for boron neutron capture therapy (BNCT). As part of this exclusive agreement, Biddle Sawyer has enlisted contract research and manufacturing organization Kinentia Biosciences to refine and streamline the drug's manufacturing process, and ultimately produce the drug in their state-of-the-art GMP facility. Kinentia Biosciences will be the exclusive manufacturer of TC220 for the US market.
Rob Hill Promoted to CEO of TAE Life Sciences as Company Pursues Global Clinical Trials
TAE Life Sciences, a pre-clinical stage biotech company focused on advancing the field of radiation oncology through accelerator-based Boron Neutron Capture Therapy (BNCT), announces the appointment of Rob Hill as its new Chief Executive Officer (CEO). Hill succeeds Bruce Bauer, a co-founder of TAE Life Sciences, who served as the company’s CEO since it was founded in 2017.
Preliminary Results Show TAE Life Sciences' Novel Boron-Containing Drug Holds Promise for Revolutionizing Boron Neutron Capture Therapy
TAE Life Sciences, a pioneering company in the field of cancer treatment, today announces the results from early testing of its TC440 boron-containing dipeptide compound for Boron Neutron Capture Therapy (BNCT). The findings suggest that TC440, along with its counterpart TC442, holds promise in revolutionizing BNCT cancer treatment.